Istaroxime
- Generic Name
- Istaroxime
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H32N2O3
- CAS Number
- 203737-93-3
- Unique Ingredient Identifier
- W8I9H2TPPL
- Indication
Investigated for use/treatment in heart disease.
- Associated Conditions
- -
- Associated Therapies
- -
Windtree To Present at the ThinkEquity Conference on October 30th
Windtree Therapeutics to present at ThinkEquity Conference on Oct 30th, discussing positive Phase 2b SEISMiC Extension Study results for istaroxime in heart failure and company strategy.
Windtree Announces Positive Phase 2b Topline Clinical
Istaroxime significantly improved systolic blood pressure, cardiac output, and renal function in heart failure patients with early cardiogenic shock, without increasing heart rate or causing clinically significant arrhythmias. NYHA classification improved up to 72 hours, with a safety profile similar to placebo.
Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial Data
Windtree Therapeutics is nearing completion of its SEISMiC Extension Phase 2b study on istaroxime for early cardiogenic shock, expecting topline data soon. The study focuses on dose optimization and SERCA2a effects for Phase 3 planning. Additionally, a parallel study for more severe cardiogenic shock patients is progressing. Windtree has a licensing agreement with Lee’s Pharmaceutical for istaroxime development in Greater China.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath